4568 Stock Overview
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide.
No risks detected for 4568 from our risk checks.
Daiichi Sankyo Company Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||JP¥3,421.00|
|52 Week High||JP¥3,558.00|
|52 Week Low||JP¥1,981.00|
|1 Month Change||-1.24%|
|3 Month Change||27.65%|
|1 Year Change||42.87%|
|3 Year Change||71.65%|
|5 Year Change||303.34%|
|Change since IPO||343.33%|
Recent News & Updates
|4568||JP Pharmaceuticals||JP Market|
Return vs Industry: 4568 exceeded the JP Pharmaceuticals industry which returned -4.7% over the past year.
Return vs Market: 4568 exceeded the JP Market which returned -4.7% over the past year.
|4568 Average Weekly Movement||5.4%|
|Pharmaceuticals Industry Average Movement||4.4%|
|Market Average Movement||4.2%|
|10% most volatile stocks in JP Market||8.5%|
|10% least volatile stocks in JP Market||2.3%|
Stable Share Price: 4568 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 4568's weekly volatility (5%) has been stable over the past year.
About the Company
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer’s disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic.
Daiichi Sankyo Company Fundamentals Summary
|4568 fundamental statistics|
Is 4568 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4568 income statement (TTM)|
|Cost of Revenue||JP¥353.33b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 29, 2022
|Earnings per share (EPS)||34.94|
|Net Profit Margin||6.41%|
How did 4568 perform over the long term?See historical performance and comparison
0.8%Current Dividend Yield
Is 4568 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4568?
Other financial metrics that can be useful for relative valuation.
|What is 4568's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 4568's PE Ratio compare to its peers?
|4568 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
4502 Takeda Pharmaceutical
4519 Chugai Pharmaceutical
4503 Astellas Pharma
4578 Otsuka Holdings
4568 Daiichi Sankyo Company
Price-To-Earnings vs Peers: 4568 is expensive based on its Price-To-Earnings Ratio (97.9x) compared to the peer average (24.7x).
Price to Earnings Ratio vs Industry
How does 4568's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 4568 is expensive based on its Price-To-Earnings Ratio (97.9x) compared to the JP Pharmaceuticals industry average (17.8x)
Price to Earnings Ratio vs Fair Ratio
What is 4568's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||97.9x|
|Fair PE Ratio||37.6x|
Price-To-Earnings vs Fair Ratio: 4568 is expensive based on its Price-To-Earnings Ratio (97.9x) compared to the estimated Fair Price-To-Earnings Ratio (37.6x).
Share Price vs Fair Value
What is the Fair Price of 4568 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4568 (¥3421) is trading below our estimate of fair value (¥8181.14)
Significantly Below Fair Value: 4568 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 4568 is poor value based on its PEG Ratio (3.4x)
Discover undervalued companies
How is Daiichi Sankyo Company forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4568's forecast earnings growth (28.8% per year) is above the savings rate (0.02%).
Earnings vs Market: 4568's earnings (28.8% per year) are forecast to grow faster than the JP market (8.9% per year).
High Growth Earnings: 4568's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 4568's revenue (12.7% per year) is forecast to grow faster than the JP market (4.5% per year).
High Growth Revenue: 4568's revenue (12.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4568's Return on Equity is forecast to be low in 3 years time (12.6%).
Discover growth companies
How has Daiichi Sankyo Company performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4568 has high quality earnings.
Growing Profit Margin: 4568's current net profit margins (6.4%) are lower than last year (7.9%).
Past Earnings Growth Analysis
Earnings Trend: 4568's earnings have grown by 11.3% per year over the past 5 years.
Accelerating Growth: 4568's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4568 had negative earnings growth (-11.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4.4%).
Return on Equity
High ROE: 4568's Return on Equity (5%) is considered low.
Discover strong past performing companies
How is Daiichi Sankyo Company's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 4568's short term assets (¥1,345.3B) exceed its short term liabilities (¥395.3B).
Long Term Liabilities: 4568's short term assets (¥1,345.3B) exceed its long term liabilities (¥475.3B).
Debt to Equity History and Analysis
Debt Level: 4568 has more cash than its total debt.
Reducing Debt: 4568's debt to equity ratio has reduced from 23.9% to 12.1% over the past 5 years.
Debt Coverage: 4568's debt is well covered by operating cash flow (85.2%).
Interest Coverage: 4568 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Daiichi Sankyo Company current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 4568's dividend (0.79%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.67%).
High Dividend: 4568's dividend (0.79%) is low compared to the top 25% of dividend payers in the JP market (3.71%).
Stability and Growth of Payments
Stable Dividend: 4568 is not paying a notable dividend for the JP market, therefore no need to check if payments are stable.
Growing Dividend: 4568 is not paying a notable dividend for the JP market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 4568 is not paying a notable dividend for the JP market.
Cash Payout to Shareholders
Cash Flow Coverage: 4568 is not paying a notable dividend for the JP market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sunao Manabe (68 yo)
Mr. Sunao Manabe, D.V.M, Ph D., has been President of Daiichi Sankyo Company, Limited since April 1, 2017 and serves as its Chief Executive Officer since June 17, 2019. Mr. Manabe served as Chief Operating...
CEO Compensation Analysis
Compensation vs Market: Sunao's total compensation ($USD1.26M) is about average for companies of similar size in the JP market ($USD1.55M).
Compensation vs Earnings: Sunao's compensation has been consistent with company performance over the past year.
Experienced Management: 4568's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: 4568's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Daiichi Sankyo Company, Limited's employee growth, exchange listings and data sources
- Name: Daiichi Sankyo Company, Limited
- Ticker: 4568
- Exchange: TSE
- Founded: 1899
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: JP¥6.557t
- Shares outstanding: 1.92b
- Website: https://www.daiichisankyo.com
Number of Employees
- Daiichi Sankyo Company, Limited
- 3-5-1, Nihonbashi-honcho
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.